Published in J Psychopharmacol on September 09, 2010
Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD) | NCT05023759
Beyond THC: The New Generation of Cannabinoid Designer Drugs. Front Behav Neurosci (2011) 2.31
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia (2014) 1.97
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol (2011) 1.81
Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev (2012) 1.67
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology (2011) 1.41
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci (2012) 1.15
Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Front Psychiatry (2013) 1.08
Heterogeneity in the composition of marijuana seized in California. Drug Alcohol Depend (2011) 1.02
Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel) (2012) 1.02
Weeding out the information: an ethnographic approach to exploring how young people make sense of the evidence on cannabis. Harm Reduct J (2013) 0.94
Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat CNS Drug Discov (2012) 0.91
Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction. Front Psychiatry (2013) 0.88
Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics (2015) 0.84
Failure to extinguish fear and genetic variability in the human cannabinoid receptor 1. Transl Psychiatry (2012) 0.83
Study the Effect of Endocannabinoid System on Rat Behavior in Elevated Plus-Maze. Basic Clin Neurosci (2015) 0.83
Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol (2012) 0.82
Developmental regulation of fear learning and anxiety behavior by endocannabinoids. Genes Brain Behav (2015) 0.82
Alcohol and cannabis use among college students: Substitutes or complements? Addict Behav (2016) 0.82
Differential effect of orexin-1 and CRF-1 antagonism on stress circuits: a fMRI study in the rat with the pharmacological stressor Yohimbine. Neuropsychopharmacology (2013) 0.81
Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis. Neuropsychopharmacology (2015) 0.81
What we know and do not know about the cannabinoid receptor 2 (CB2). Semin Immunol (2014) 0.81
Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety Disord (2012) 0.80
Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br J Pharmacol (2017) 0.79
Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med (2015) 0.79
Marijuana use and viral suppression in persons receiving medical care for HIV-infection. Am J Drug Alcohol Abuse (2016) 0.78
Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. Neurotherapeutics (2015) 0.78
Modulation of cognitive and emotional processing by cannabidiol: the role of the anterior cingulate cortex. Front Hum Neurosci (2013) 0.78
Cannabidiol Modulates Fear Memory Formation Through Interactions with Serotonergic Transmission in the Mesolimbic System. Neuropsychopharmacology (2016) 0.77
Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm Reduct J (2012) 0.77
A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol. Front Pharmacol (2017) 0.76
Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life. Front Pharmacol (2017) 0.76
Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report. Integr Med (Encinitas) (2015) 0.75
Screening Medications for the Treatment of Cannabis Use Disorder. Int Rev Neurobiol (2016) 0.75
Safety and Toxicology of Cannabinoids. Neurotherapeutics (2015) 0.75
Gene × Environment Interactions in Schizophrenia: Evidence from Genetic Mouse Models. Neural Plast (2016) 0.75
Overlapping Mechanisms of Stress-Induced Relapse to Opioid Use Disorder and Chronic Pain: Clinical Implications. Front Psychiatry (2016) 0.75
Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. Perm J (2016) 0.75
Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition. Curr Addict Rep (2017) 0.75
A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders. Clin Psychopharmacol Neurosci (2017) 0.75
Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet (2003) 4.91
Regionally localized thinning of the cerebral cortex in schizophrenia. Arch Gen Psychiatry (2003) 4.84
Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry (2009) 3.67
The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations. Neurosci Biobehav Rev (2007) 2.25
Diffusion tensor imaging in schizophrenia. Biol Psychiatry (2005) 2.14
[Brain effects of cannabis--neuroimaging findings]. Rev Bras Psiquiatr (2005) 2.05
White matter integrity and cognitive impairment in first-episode psychosis. Am J Psychiatry (2010) 1.92
Regional gray matter volume abnormalities in the at risk mental state. Biol Psychiatry (2006) 1.81
Tract-specific anisotropy measurements in diffusion tensor imaging. Psychiatry Res (2005) 1.79
Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry (2013) 1.76
Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry (2009) 1.69
Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev (2012) 1.67
Effect of BDNF val(66)met polymorphism on declarative memory and its neural substrate: a meta-analysis. Neurosci Biobehav Rev (2012) 1.62
Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology (2009) 1.62
Neural systems underlying British Sign Language and audio-visual English processing in native users. Brain (2002) 1.60
Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One (2013) 1.59
The phenomenology and neurobiology of delusion formation during psychosis onset: Jaspers, Truman symptoms, and aberrant salience. Schizophr Bull (2013) 1.58
Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull (2012) 1.58
Heart failure: comparison between six-minute walk test and cardiopulmonary test. Arq Bras Cardiol (2011) 1.55
Resting-state functional connectivity in normal brain aging. Neurosci Biobehav Rev (2013) 1.55
Cavum septum pellucidum and adhesio interthalamica in schizophrenia: an MRI study. Eur Psychiatry (2006) 1.54
Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry (2010) 1.52
Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry (2009) 1.49
Psychometric properties of the Fagerström Test for Nicotine Dependence. J Bras Pneumol (2009) 1.46
Neurostructural predictors of Alzheimer's disease: a meta-analysis of VBM studies. Neurobiol Aging (2009) 1.46
Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res (2008) 1.43
Functional neuroimaging of minocycline's effect in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.43
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology (2011) 1.41
Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry (2009) 1.40
Duloxetine in the treatment of social anxiety disorder. J Clin Psychopharmacol (2007) 1.40
Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol (2009) 1.40
Glutamatergic dysfunction in OCD. Neuropsychopharmacology (2005) 1.36
The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study. Brain (2003) 1.35
Pattern of neural responses to verbal fluency shows diagnostic specificity for schizophrenia and bipolar disorder. BMC Psychiatry (2011) 1.34
Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology (2005) 1.32
Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum Brain Mapp (2009) 1.32
Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl (2007) 1.31
Regional gray matter abnormalities in obsessive-compulsive disorder: a voxel-based morphometry study. Biol Psychiatry (2005) 1.30
Acoustic noise and functional magnetic resonance imaging: current strategies and future prospects. J Magn Reson Imaging (2002) 1.29
Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry (2012) 1.29
Neural correlates of executive function and working memory in the 'at-risk mental state'. Br J Psychiatry (2009) 1.29
Alterations in white matter evident before the onset of psychosis. Schizophr Bull (2012) 1.29
Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry (2008) 1.24
What causes the onset of psychosis? Schizophr Res (2005) 1.24
Dissociating linguistic and nonlinguistic gestural communication in the brain. Neuroimage (2004) 1.24
Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol Sci (2008) 1.24
The very preterm brain in young adulthood: the neural correlates of verbal paired associate learning. J Pediatr (2010) 1.22
An fMRI study of verbal self-monitoring: neural correlates of auditory verbal feedback. Cereb Cortex (2005) 1.22
Localized cerebral blood flow reductions in patients with heart failure: a study using 99mTc-HMPAO SPECT. J Neuroimaging (2005) 1.20
Misattribution of speech and impaired connectivity in patients with auditory verbal hallucinations. Hum Brain Mapp (2007) 1.20
Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology (2012) 1.19
Co-occurring mental and substance abuse disorders: a review on the potential predictors and clinical outcomes. Psychiatry Res (2010) 1.19
Inner speech models of auditory verbal hallucinations: evidence from behavioural and neuroimaging studies. Int Rev Psychiatry (2007) 1.17
White matter alterations in early stages of schizophrenia: a systematic review of diffusion tensor imaging studies. J Neuroimaging (2013) 1.17
Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. Br J Psychiatry Suppl (2007) 1.16
White matter defects in first episode psychosis patients: a voxelwise analysis of diffusion tensor imaging. Neuroimage (2009) 1.15
Dhat syndrome: a systematic review. Psychosomatics (2013) 1.15
Neuroanatomy of auditory verbal hallucinations in schizophrenia: a quantitative meta-analysis of voxel-based morphometry studies. Cortex (2012) 1.14
Volumetric reduction of the corpus callosum in Alzheimer's disease in vivo as assessed with voxel-based morphometry. Psychiatry Res (2006) 1.13
Fronto-temporal interactions during overt verbal initiation and suppression. J Cogn Neurosci (2008) 1.13
Whither the attenuated psychosis syndrome? Schizophr Bull (2012) 1.12
Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol (2009) 1.12
Brain structural abnormalities at the onset of schizophrenia and bipolar disorder: a meta-analysis of controlled magnetic resonance imaging studies. Curr Pharm Des (2012) 1.11
Brain connectivity abnormalities predating the onset of psychosis: correlation with the effect of medication. JAMA Psychiatry (2013) 1.11
Structural brain differences in patients with schizophrenia and schizotypal disorder demonstrated by voxel-based morphometry. Eur Arch Psychiatry Clin Neurosci (2004) 1.11
Regional gray matter abnormalities in panic disorder: a voxel-based morphometry study. Psychiatry Res (2008) 1.11
Age-related gray matter volume changes in the brain during non-elderly adulthood. Neurobiol Aging (2009) 1.10
State-dependent microstructural white matter changes in bipolar I depression. Eur Arch Psychiatry Clin Neurosci (2009) 1.10